# A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma

> **NCT03294083** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **SillaJen, Inc.** · enrollment: 89 (actual)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **BIOLOGICAL:** Pexastimogene Devacirepvec (Pexa-Vec)
- **BIOLOGICAL:** Cemiplimab

## Key facts

- **NCT ID:** NCT03294083
- **Lead sponsor:** SillaJen, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-06-07
- **Primary completion:** 2023-08
- **Final completion:** 2023-11
- **Target enrollment:** 89 (ACTUAL)
- **Last updated:** 2022-10-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03294083

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03294083, "A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03294083. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*